- Published on
Emergency and Acute Medicine – Alcohol Withdrawal
Alcohol Withdrawal is the most common withdrawal syndrome encountered in the emergency department and represents a spectrum of neuroexcitatory symptoms that occur after cessation or reduction of chronic alcohol use. The underlying mechanism involves neuroadaptation: chronic alcohol exposure enhances inhibitory GABA activity and suppresses excitatory NMDA receptors. When alcohol intake stops, this balance shifts toward excess excitation, leading to autonomic hyperactivity and neurologic symptoms. Repeated withdrawal episodes may worsen severity through a process known as kindling, increasing the risk of life-threatening complications.
Alcohol withdrawal progresses through a predictable timeline with four major clinical stages. Early withdrawal begins within 6–8 hours after the last drink and lasts 1–2 days, presenting with tremulousness, anxiety, palpitations, nausea, and anorexia. Withdrawal seizures typically occur between 6–48 hours and are usually brief, generalized seizures. Alcoholic hallucinosis develops within 12–48 hours and is characterized by visual (most common), tactile, or auditory hallucinations, often with a relatively clear sensorium. The most severe form, delirium tremens (DTs), occurs 48–96 hours after cessation and may last up to 5 days, presenting with tachycardia, hypertension, diaphoresis, agitation, and delirium. DTs occur in approximately 5% of patients but carry a high mortality rate of 5–15%.
Diagnosis is primarily clinical, based on history and physical examination. Key historical features include the time of last alcohol intake, history of prior withdrawal episodes, and severity of previous symptoms. Physical examination should focus on vital signs and signs of autonomic instability. Laboratory evaluation typically includes electrolytes, renal function, glucose, magnesium, CBC, and blood alcohol level, as well as screening for coexisting conditions such as infection. Imaging such as CT of the head is reserved for patients with altered mental status or unclear diagnosis.
Management begins with initial stabilization, including airway, breathing, and circulation, IV access, fluid resuscitation, and continuous monitoring. The cornerstone of treatment is benzodiazepines, which act by enhancing GABA activity and reducing CNS hyperexcitability. Commonly used agents include Diazepam (5–10 mg IV, repeat as needed; 5–20 mg PO for mild symptoms) and Lorazepam (2 mg IV or PO every 2–4 hours as needed). High or repeated dosing is often required to adequately control symptoms.
In severe or refractory cases, adjunctive therapies such as Phenobarbital (15–20 mg/kg IV for severe symptoms or status epilepticus) or Propofol (25–75 μg/kg/min infusion) may be used, particularly in ICU settings. Supportive care includes correction of electrolyte abnormalities and monitoring for complications such as arrhythmias or aspiration.
Disposition depends on severity. Patients with moderate-to-severe withdrawal, persistent symptoms, delirium tremens, or significant comorbidities require hospital admission, often to a monitored or intensive care setting. Patients with mild symptoms that respond well to therapy may be discharged with close follow-up and referral to a detoxification program.
A key clinical pearl is to avoid under-treatment with benzodiazepines, as inadequate dosing can lead to progression to severe withdrawal or DTs. Additionally, clinicians must remain vigilant for alternative diagnoses, as medical conditions such as infection, hypoglycemia, or intracranial pathology may mimic or coexist with alcohol withdrawal.
0 Comments
